Researchers are currently conducting a clinical trial, called the SPECIAL study, to investigate the safety and efficacy of the PCSK9 inhibitor Evolocumab in patients with non‐ST segment elevation ACS and multivessel CAD, who have undergone culprit vessel revascularization. The gene discussed is PCSK9; the disease is coronary artery disorder.